2020
DOI: 10.1111/apm.13038
|View full text |Cite
|
Sign up to set email alerts
|

Gut microbiota in atherosclerosis: focus on trimethylamine N‐oxide

Abstract: in atherosclerosis: focus on trimethylamine N-oxide. APMIS 2020; 128: 353-366.The increasing prevalence of cardiovascular diseases cannot adequately be explained by traditional risk factors. Recently, accumulating evidence has suggested that gut microbiota-derived numerous metabolites are contributors to atherosclerotic events. Among them, the role of trimethylamine N-oxide (TMAO) in promoting atherosclerosis has gained attention. TMAO is reported to exert the proatherogenic effects by impacting on the traditi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
94
0
4

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 125 publications
(98 citation statements)
references
References 119 publications
(159 reference statements)
0
94
0
4
Order By: Relevance
“…Methylglyoxal is a product of glucose and glycine metabolism that increases the activity of the gut microbial trimethylamine (TMA)-lyase [ 46 ]. TMA lyase catalyzes the transformation of dietary choline and carnitine to TMA, which in turn is metabolized by the liver to trimethylamine-N-oxide (TMAO), a potential risk factor for cardiovascular diseases [ 47 ]. The pan-genome of the Liebefeld selection covers the superpathway “methylglyoxal degradation IV” similarly to subjects MH0002 and MH0003.…”
Section: Resultsmentioning
confidence: 99%
“…Methylglyoxal is a product of glucose and glycine metabolism that increases the activity of the gut microbial trimethylamine (TMA)-lyase [ 46 ]. TMA lyase catalyzes the transformation of dietary choline and carnitine to TMA, which in turn is metabolized by the liver to trimethylamine-N-oxide (TMAO), a potential risk factor for cardiovascular diseases [ 47 ]. The pan-genome of the Liebefeld selection covers the superpathway “methylglyoxal degradation IV” similarly to subjects MH0002 and MH0003.…”
Section: Resultsmentioning
confidence: 99%
“…A significant hallmark of atherosclerosis is the accumulation of pro-inflammatory Macs and dendritic cells (DCs) in coronary arteries that respond to pro-atherogenic stimuli, such as free fatty acids (FFAs) and oxidized LDLs (oxLDLs), and the failure to digest lipids that contribute to the formation of foam cells in atherosclerotic plaques [ 16 , 17 ]. Mechanisms that reduce Mac/DC inflammation, increase lipid degradation, and prevent foam cell formation would all decrease atherosclerosis progression.…”
Section: Microbiota-derived Metabolites Associated With Atherosclementioning
confidence: 99%
“…TMA is a metabolic precursor that is converted to a trimethylamine N-oxide (TMAO) in the liver. TMAO drives atherosclerosis progression [110], in part, by regulating macrophage activation and foam cell formation, platelet activation, and aggregation, resulting in elevated expression of IL-1β, IL-6, and TNFα inflammatory cytokines [134]. Recent work implies that TMAO could be also involved in metabolic dysfunction and activation of inflammation, directly acting via its receptor protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) [135].…”
Section: Intestinal Microbiota In Cvd Developmentmentioning
confidence: 99%